Daratumumab for HIV-related lymphomas and Castleman disease
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a drug called daratumumab for people with certain HIV-related blood cancers (primary effusion lymphoma, plasmablastic lymphoma) or a related condition called multicentric Castleman disease that has come back or not improved after standard treatment. The drug targets a protein on cancer cells to help the immune system attack them. It might be a new option when standard chemotherapy isn't working or isn't suitable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have primary effusion lymphoma, plasmablastic lymphoma, or HIV-related multicentric Castleman disease that has returned or not responded to earlier treatment, OR you cannot have standard first-line chemotherapy.
- If you have HIV, you must be on effective anti-HIV medication and have an undetectable viral load (under 200 copies per mL).
- Your blood counts and kidney function need to be within certain limits (e.g., hemoglobin above 7 g/dL, kidney clearance of at least 15 mL/min).
- If you have Castleman disease, you must show at least one symptom (like fever, fatigue, rash) and one lab test abnormality (like low red blood cells, low platelets, low albumin).
- You must have recovered from side effects of prior cancer treatments (except hair loss and nerve pain) and have not had cancer treatment in the last 2 weeks.
- You must not be pregnant or breastfeeding, and you (and your partner) need to use effective birth control during and for 3 months after the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immune therapy drugs (durvalumab and tremelimumab) given with chemotherapy in people with stage IV non-small cell lung cancer who also have HIV. It may help shrink or control cancer by boosting the immune response while keeping HIV well controlled.
This trial is for people with multiple myeloma or AL amyloidosis who are about to start treatment with a drug called daratumumab. It compares two places to inject the medicine (thigh vs. abdomen) to see which works better and is more comfortable.
This trial tests a new combination of a targeted drug (daratumumab) plus chemotherapy, followed by a stem cell transplant, for people with a rare and aggressive blood cancer called primary plasma cell leukemia. The goal is to see if adding daratumumab improves the chances of getting rid of the cancer and staying in remission.
This early-phase trial tests daratumumab combined with a dose-adjusted chemotherapy plan (EPOCH) to treat plasmablastic lymphoma. It aims to improve how well the cancer responds, including in people living with HIV or without HIV.
This trial tests how well a combination of daratumumab, bortezomib, and dexamethasone works in people with plasmablastic lymphoma that has returned or did not respond to prior treatment. It aims to shrink measurable tumors and improve outcomes, including for some people living with HIV.
This trial tests if adding the drug daratumumab can clear remaining cancer cells in people with T-cell acute lymphoblastic leukemia (T-ALL) who still have a small amount of leukemia after initial chemotherapy. It aims to reduce the risk of the cancer coming back.
Hear when a new Lymphoma, Primary Effusion trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.